| Pulmonary | Extrapulmonary | p-value |
---|---|---|---|
Total Patients, n/N (%) | 169/191 (88) | 22/191 (12) | Â |
Median Age, years (Range) | 45d (6–75) | 21 (6–90) | < 0 .001 |
Gender, n/N (%) | |||
 Male | 103/169 (61) | 7/22 (32) | 0.009 |
 Female | 66/169 (39) | 15/22 (68) |  |
Treatment historya, n/N (%) | |||
 Single cycle of RHEZb | 82/169 (48) | 2/22 (9) | < 0 .001 |
 One or more cycles of RHEZSc | 28/169 (17) | 0/22 (0) | |
 Unknown | 34/169 (20) | 5/22 (23) | |
 Not Treated | 25/169 (15) | 15/22 (68) | |
HIV Status, n/N (%) | |||
 Negative | 22/169 (13) | 0/22 (0) | 0.936 |
 Unknown | 147/169 (87) | 22/22 (100) | |
Sites involved, n/N (%) | |||
 Lung | 169/169 (100) | – |  |
 Lymph nodes | – | 7/22 (32) |  |
 Pleural fluid | – | 8/22 (36) |  |
 Pus | – | 3/22 (14) |  |
 Tissue | – | 3/22 (14) |  |
 Perinephric fluid | – | 1/22 (4) |  |